Safety and efficacy of percutaneous image‐guided ablation for soft tissue sarcoma metastases to the liver

Ahmed Awad,Koustav Pal,Steven Yevich,Joshua D. Kuban,Alda Tam,Bruno C. Odisio,Sanjay Gupta,Peiman Habibollahi,Andrew J. Bishop,Anthony Paul Conley,Neeta Somaiah,Dejka M. Araujo,Maria Alejandra Zarzour,Ravin Ratan,Christina L. Roland,Emily Z. Keung,Steven Y. Huang,Rahul A. Sheth
DOI: https://doi.org/10.1002/cncr.35330
IF: 6.9209
2024-04-22
Cancer
Abstract:Purpose To evaluate outcomes following percutaneous image‐guided ablation of soft tissue sarcoma metastases to the liver. Materials and Methods A single‐institution retrospective analysis of patients with a diagnosis of metastatic soft tissue sarcoma who underwent percutaneous image‐guided ablation of hepatic metastases between January 2011 and December 2021 was performed. Patients with less than 60 days of follow‐up after ablation were excluded. The primary outcome was local tumor progression‐free survival (LPFS). Secondary outcomes included overall survival, liver‐specific progression‐free survival. and chemotherapy‐free survival. Results Fifty‐five patients who underwent percutaneous ablation for 84 metastatic liver lesions were included. The most common histopathological subtypes were leiomyosarcoma (23/55), followed by gastrointestinal stromal tumor (22/55). The median treated liver lesions was 2 (range, 1–8), whereas the median size of metastases were 1.8 cm (0.3–8.7 cm). Complete response at 2 months was achieved in 90.5% of the treated lesions. LPFS was 83% at 1 year and 80% at 2 years. Liver‐specific progression‐free survival was 66% at 1 year and 40% at 2 years. The overall survival at 1 and 2 years was 98% and 94%. The chemotherapy‐free holiday from the start of ablation was 71.2% at 12 months. The complication rate was 3.6% (2/55); one of the complications was Common Terminology Criteria for Adverse Events grade 3 or higher. LPFS subgroup analysis for leiomyosarcoma versus gastrointestinal stromal tumor suggests histology‐agnostic outcomes (2 years, 89% vs 82%, p = .35). Conclusion Percutaneous image‐guided liver ablation of soft tissue sarcoma metastases is safe and efficacious.
oncology
What problem does this paper attempt to address?